AstraZeneca Stock Falls After Breast Cancer Treatment Fails In Pivotal Trial
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.
A pill from AstraZeneca failed to improve outcomes in a closely watched breast cancer study, a result that could limit the use of the medicine.
AstraZeneca
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.”
IBD — AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer“A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.”
stat news — STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial